Our R&D team is committed to the identification and development of promising new candidates that target orphan diseases and unmet medical needs in the field of oncology, cardiology, neurology and inflammation. By integrating diagnostics and therapy (theragnostics), we work towards targeted and personalized medicine that tailors treatments to individual patient needs.
Our senior R&D management group directs the overall strategy for developing our pipeline of investigational candidates, while strictly adhering to international radiopharmaceutical regulations and guidelines. The R&D management group has significant expertise and know-how across the entire product development chain and is supported by experienced staff in radiochemistry, pharmaceutical, pre-clinical and clinical development. In addition, we maintain continuous interactions with hospitals, universities and research centers of excellence as part of our strategy to foster a robust R&D pipeline.